“Also good to model core organic revenue growth in Q3 1% higher than we delivered in Q2.”

In context

“to expect adjusted income tax rate will be 10.5% in 2024, and for the year we're assuming between $1.3 billion and $1.5 billion in net capital expenditures and free cash flow in the range of $6.5 billion to $7 billion. In terms of capital deployment, we're assuming $3 billion of share buybacks, which were already completed in January. Expect to return approximately $600 million of capital to shareholders this year through dividends and we deployed $3.1 billion to acquire Olink shortly after the Q2 close. Full-year average diluted share count is assumed to be approximately 383 million shares. Finally, I wanted to touch on quarterly phasing to help you with your modeling. Relative to the midpoint of the guide, I recommend modeling Q3 organic revenue growth 1% higher than we delivered in Q2. Also good to model core organic revenue growth in Q3 1% higher than we delivered in Q2. And in terms of adjusted EPS in Q3, I recommend modeling it to be just over 24% of the full-year. So to conclude, we continue to deliver on our commitments. And at the halfway point, we're in a great position to deliver differentiated performance for all our stakeholders in 2024. With that I'll turn the call back over to Raf. Rafael Tejada: Operator, we're ready for the Q&A portion of the call. Operator: Thank you. [Operator Instructions] Our first question is from Michael Ryskin with Bank of America. Michael, your line is now open. Please go ahead. Michael Ryskin: Great. Thanks for taking the questions, guys. Congrats on the quarter. Marc, a high-level one for you to start off maybe, at our Vegas Health Care Conference in May, you made some initial comments about 2025 market expectations”